116 related articles for article (PubMed ID: 38940003)
1. A longitudinal study on SARS-CoV-2 seroconversion, reinfection and neutralisation spanning several variant waves and vaccination campaigns, Heinsberg, Germany, April 2020 to November 2022.
Schulte B; Richter E; Büning A; Baum M; Breuer A; Zorn J; König J; Geiger M; Eschbach-Bludau M; Heuser J; Zölzer D; Korencak M; Hollstein R; Beins E; Emmert D; Aldabbagh S; Eis-Hübinger AM; Streeck H
Euro Surveill; 2024 Jun; 29(26):. PubMed ID: 38940003
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
3. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
4. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
5. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
6. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study.
Guo L; Zhang Q; Gu X; Ren L; Huang T; Li Y; Zhang H; Liu Y; Zhong J; Wang X; Chen L; Zhang Y; Li D; Fang M; Xu L; Li H; Wang Z; Li H; Bai T; Liu W; Peng Y; Dong T; Cao B; Wang J
Lancet Microbe; 2024 Jan; 5(1):e24-e33. PubMed ID: 38048805
[TBL] [Abstract][Full Text] [Related]
7. Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.
Hyun H; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
Front Immunol; 2024; 15():1385135. PubMed ID: 38756783
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
[TBL] [Abstract][Full Text] [Related]
9. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
[TBL] [Abstract][Full Text] [Related]
10. A cross-sectional study of SARS-CoV-2 antibodies among healthcare workers in a tertiary care hospital in Taiwan: implications for protection against the Omicron variants.
Chen CH; Chao DY; Kor CT; Kuo SF; Lin JS; Lai HW; Liu YT; Lin CH; Chen MK
BMC Infect Dis; 2024 May; 24(1):529. PubMed ID: 38802771
[TBL] [Abstract][Full Text] [Related]
11. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
12. Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity.
Merkt S; Ali S; Gudina EK; Adissu W; Gize A; Muenchhoff M; Graf A; Krebs S; Elsbernd K; Kisch R; Betizazu SS; Fantahun B; Bekele D; Rubio-Acero R; Gashaw M; Girma E; Yilma D; Zeynudin A; Paunovic I; Hoelscher M; Blum H; Hasenauer J; Kroidl A; Wieser A
Nat Commun; 2024 Apr; 15(1):3463. PubMed ID: 38658564
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
14. Characterizing Infections in Two Epidemic Waves of SARS-CoV-2 Omicron Variants: A Cohort Study in Guangzhou, China.
Qu L; Xie C; Qiu M; Yi L; Liu Z; Zou L; Hu P; Jiang H; Lian H; Yang M; Yang H; Zeng H; Chen H; Zhao J; Xiao J; He J; Yang Y; Chen L; Li B; Sun J; Lu J
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675989
[TBL] [Abstract][Full Text] [Related]
15. The contributions of vaccination and natural infection to the production of neutralizing antibodies against the SARS-CoV-2 prototype strain and variants.
Xie H; Zhang J; Bai S; Lv M; Li J; Chen W; Suo L; Chen M; Zhao W; Zhou S; Wang J; Zhang A; Ma J; Wang F; Yan L; Li D; Wu J
Int J Infect Dis; 2024 Jul; 144():107060. PubMed ID: 38670482
[TBL] [Abstract][Full Text] [Related]
16. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.
Hönning A; Tomczyk S; Hermes J; Grossegesse M; Hofmann N; Michel J; Neumann M; Nitsche A; Hoppe B; Eckmanns T; Schmidt-Traub H; Zappel K
BMC Infect Dis; 2024 Apr; 24(1):436. PubMed ID: 38658874
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
[TBL] [Abstract][Full Text] [Related]
18. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
20. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
